Skip to content

Net Change in Cash at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
-$13M+70.5%
Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
-$437.45K+84.7%
PTH
Pelthos Therapeutics Inc.PTHS
$14.2M+3,818%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
-$8.15M+55.3%
HRO
HarrowHROW
$21.72M+11.5%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$46.69M-26.0%

Other financials

Income statement

See full
Revenue$16.0M+21.5%
Gross profit$9.7M+16.7%
Operating income-$1.5M+55.1%
Net income-$2.2M+45.2%
EPS (diluted)-$0.08+55.6%

Balance sheet

See full
Cash & equivalents$27.2M+29.2%
Total debt$25.5M+1.2%
Total equity$30.8M+43.1%
Total assets$91.5M+7.7%

Cash flow

See full
Operating cash flow$2.9M+203%
CapEx$3.8M
Free cash flow-$6.0M

Valuation

See full
Market cap$194.94M+20.9%
Enterprise value$193.19M+16.2%
P/S+0.2×

Profitability

See full
Gross margin65.4%-1.0pp
Operating margin-9.8%
Net margin-14.8%
FCF margin-43%

Returns & leverage

See full
Return on equity-36.6%
Debt / equity0.8×-0.3×
Current ratio1.7×+0.4×

Where this comes from

Reported directly by Journey Medical Corporation in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Journey Medical Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Journey Medical Corporation's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Journey Medical Corporation's net change in cash?
Journey Medical Corporation (DERM) reported net change in cash of $3.13M in Q1 2026.
How has Journey Medical Corporation's net change in cash changed year-over-year?
Journey Medical Corporation's net change in cash increased by 309.0% year-over-year, from $765K to $3.13M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.